Bayer AG reported positive results for elinzanetant in women with or at high risk of a type of breast cancer, broadening the ...

Thursday, Bayer shared top-line data from a phase 3 trial that tested elinzanetant in women on adjuvant endocrine therapy for ...

Bayer (BAYZF) (BAYRY) says elinzanetant, its experimental therapy for hot flashes, reached the main goals in a late-stage ...

Vasomotor symptoms are a common problem in women with HR-positive breast cancer receiving anti-cancer therapy.

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

I did not finish that yoga class. Instead, I rolled up my mat and fled the studio for the air-conditioned bathroom where I ...

As Bayer awaits an FDA decision on its non-hormonal treatment for hot flashes caused by menopause, it's unveiling new results ...

(RTTNews) - Bayer Aktiengesellschaft (BAYRY.PK), Thursday announced that Elinzanetant, a non-hormonal drug, has met all primary and second endpoints in the Phase III study OASIS 4, investigating the ...

Medically reviewed by Renita White, MD Perimenopause is the transition period when the female body starts to shift from ...

The menopausal transition is an opportunity for women to cross a psychological threshold into the second half of life, but ...

Trial confirms elinzanetant's efficacy and safety in addressing vasomotor symptoms caused by adjuvant endocrine therapy in ...

Many of us use our Christmas spa vouchers as soon as we possibly can in January – about 15 per cent are redeemed then, the ...